On January 15, 2025, Sun Pharma share price traded down by 1.05% at 11:58 AM (IST) at ₹1749.80, up for the second con while the BSE benchmark Sensex gained 269.62 points to 76,769.26. Sun Pharma’s share price reached a 52-week high of ₹1,960.23 on November 30, 2024, and a 52-week low of ₹1,290.70 on January 18, 2024. As per BSE, the total traded volume for the stock stood at 6,137 shares with a turnover of ₹1.07 crore.
At the current price, Sun Pharma shares are trading at a price-to-earnings (P/E) ratio of 156.09x, based on its trailing 12-month earnings per share (EPS) of ₹11.21, and a price-to-book (P/B) ratio of 17.80, according to exchange data.
As of September 30, 2024, Foreign Institutional Investors (FIIs) held an 18.01% stake in Sun Pharma shares, while Domestic Institutional Investors (DIIs) owned 18.48%, and the promoters held 54.48%.
Sun Pharma reported a consolidated net profit of ₹3,040 crore for the second quarter, up from ₹2,375 crore in the same period last year. Revenue from operations during the quarter rose to ₹13,291 crore.
The company’s EBITDA for the period stood at ₹3,939 crore, while formulation sales in India surged to ₹4,265 crore. For the first half of the fiscal year, Indian formulation sales totalled ₹8,410 crores.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jan 15, 2025, 1:15 PM IST
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
